Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score

Area of Science:

• Urology
• Oncology
• Molecular Biology

Background:

• Prostate cancer incidence is rising globally.
• The prostate-specific antigen (PSA) test has limitations in specificity, leading to unnecessary procedures.
• New biomarkers are crucial for accurate prostate cancer diagnosis and management.

Purpose of the Study:

• To review the current research on Prostate Cancer gene 3 (PCA3) as a novel biomarker.
• To explore the potential applications of PCA3 in prostate cancer diagnosis, prognosis, and therapy.
• To discuss the future prospects of PCA3 in clinical practice.

Main Methods:

• Review of existing scientific literature on PCA3.
• Analysis of PCA3's performance in distinguishing prostate cancer from other conditions.
• Examination of studies on PCA3's genetic sequence, cellular proliferation effects, and impact on tumor-related genes/proteins.

Main Results:

• PCA3 demonstrates high specificity and sensitivity for prostate cancer detection.
• A PCA3 score has been developed and utilized in various research studies.
• Preliminary in vitro studies show potential for PCA3 in targeted therapy.

Conclusions:

• PCA3 is a highly promising biomarker for enhancing prostate cancer diagnosis accuracy.
• PCA3 holds potential for early detection, patient follow-up, prognosis prediction, and targeted therapy.
• Further research and clinical application of PCA3 are warranted for its full potential to be realized.